Exorbitant prices are just one reason to loathe the company that makes the EpiPenByOliver StaleyPublishedAugust 24, 2016
Indian pharma majors will make one of the most popular cholesterol drugs in the USByMadhura KarnikPublishedJuly 22, 2016
This chart of Viagra’s uplifting effect on drug prices is the greatest thing everByJason KaraianPublishedMay 13, 2016
Karmic justice inflicted on pharma company that buys drugs and jacks-up pricesByAlison GriswoldPublishedMarch 15, 2016
Name-brand prescription drug prices in the US have doubled in the last five yearsByAshley RodriguezPublishedMarch 15, 2016
Pfizer and Allergan just announced the second-largest corporate M&A deal of all timeByMatt PhillipsPublishedNovember 23, 2015
Mylan’s chairman wrote a brutal, 3,000-word letter attempting to shoot down a takeover attemptByMax NisenPublishedApril 27, 2015
Amgen, under pressure, moves to boost profitability—but that’s hurting earnings in the short termByBrian BrowdiePublishedOctober 27, 2014
The pharma industry’s blockbuster $29 billion, three-way deal is all about specializationByHeather TimmonsPublishedApril 22, 2014
Daiichi Sankyo’s Ranbaxy sell-off highlights the pitfalls of making drugs in IndiaByHeather TimmonsPublishedApril 7, 2014
Ireland’s massive pharmaceutical sector had a terrible quarter, but the Irish don’t seem to mindByMatt PhillipsPublishedMarch 13, 2014
Chlamydia just became the most commonly reported disease ever in the US—but there’s something worseByRachel FeltmanPublishedJanuary 9, 2014
The world needs made-in-China vaccines, despite a recent spate of deathsByLily KuoPublishedJanuary 3, 2014
